Amphastar Pharmaceuticals, Inc. (AMPH) fair value analysis
Nasdaq · Updated 2026-10-19
AMPH price how computed
Forward Fair Value verdict
UndervaluedAMPH is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $25.87
- Sector
- Healthcare
- 12-month range
- $16.87–$29.40
- Market cap
- $1.1B
- From 52-week high
- -12.0%
- Shares outstanding
- 42.5M
- Rank in Healthcare by discount to fair value
- #27 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Amphastar Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and markets specialty and generic injectable pharmaceutical products. The company operates primarily in the United States, serving healthcare providers and patients through its portfolio of medications and drug delivery systems.
AMPH currently ranks #27 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.1B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $730M
- Net margin
- 10.8%
- EPS (TTM)
- $2.76
- Gross margin
- 50.8%
- Debt / equity
- 0.90
- Revenue growth (3-yr avg)
- 0.6%
- Shares outstanding
- 42.5M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $23.70
- 200-day average
- $22.32
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+56.9%)
2026-03 ▼ miss (-40.8%)
2025-12 ▼ miss (-31.5%)
2025-09 ▲ beat (+12.0%)
2025-06 ▲ beat (+17.2%)
2025-03 ▲ beat (+7.2%)
2024-12 ▼ miss (-2.0%)
2024-09 ▼ miss (-2.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 0 buy · 6 hold · 1 sell (7 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $22.5
- Target vs last price
- -13.0%
What our data shows for AMPH
- Our model validated 17 trailing price-to-earnings windows for AMPH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $16.87–$29.40.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AMPH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AMPH news
TickrTrends' derived news-sentiment signal for AMPH is currently leaning positive, computed from recent coverage.
- A Look at Amphastar Pharmaceuticals Inc (AMPH) After 3.3% Decline -- GF Value $36.36 vs Price $25.81 (gurufocus.com, 2026-10-01)
TickrTrends take: Amphastar Pharmaceuticals operates in the Healthcare sector and is currently trading below the GF Value estimate, which aligns with TickrTrends' undervalued assessment. The recent decline presents a potential opportunity for value-focused investors to monitor whether the stock's price movement reflects fundamental weakness or simply a temporary pullback from fair value. Investors should watch for developments in the company's pipeline and financial performance that could explain the current discount and determine if the undervalued signal remains valid. - Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 5.2% Rally? GF Value Says Undervalued (gurufocus.com, 2026-09-25)
TickrTrends take: Amphastar Pharmaceuticals has recently gained 5% in price, yet TickrTrends currently assesses the stock as undervalued, suggesting the recent rally may not have fully corrected the valuation gap. For investors focused on valuation metrics in the Healthcare sector, the persistence of an undervalued rating despite the price movement indicates that fundamental value may still exceed current market pricing. Valuation-focused readers should monitor whether further price appreciation aligns with closing this valuation gap or if the stock remains disconnected from intrinsic value estimates. - A Look at Amphastar Pharmaceuticals Inc (AMPH) After 3.3% Gain -- GF Value $35.96 vs Price $23.74 (gurufocus.com, 2026-09-03)
TickrTrends take: Amphastar Pharmaceuticals trades below its GF Value estimate, which aligns with TickrTrends' undervalued assessment for this Healthcare sector company. The gap between the current price and estimated intrinsic value suggests the stock may warrant attention from investors focused on valuation metrics. Readers tracking AMPH should monitor whether the company's fundamentals support a closer convergence toward the higher valuation benchmark over time.
What people are saying
Follow the AMPH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — AMPH's momentum indicator declined this week, shifting from a positive A rating to none, suggesting a loss of upward price movement direction. The stock maintains an undervalued valuation verdict within the Healthcare sector. This change in momentum warrants attention from investors monitoring AMPH's technical trajectory alongside its fundamental valuation position.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — AMPH remains undervalued according to current analysis. The relative strength index moved from overbought territory into a neutral zone this week, while the stock's sector discount ranking declined from number 34 to number 39 among Healthcare sector companies.
- 2026-10-05 — AMPH's 50/200-day trend state has shifted from mixed to uptrend this week, indicating improving momentum in the stock's short-term and intermediate-term price movements. The stock maintains an undervalued valuation verdict according to TickrTrends' derived indicators. This trend improvement reflects a positive technical development for the Healthcare sector company.
- 2026-09-28 — AMPH's momentum indicator improved this week from B to A, while its RSI entered overbought territory after being in the neutral zone previously. The stock's sector discount rank declined from number 26 to number 34, indicating a weaker relative valuation position within the Healthcare sector. Despite these technical shifts showing increased price strength, the stock maintains an undervalued verdict according to current valuation assessments.
- 2026-09-21 — AMPH's momentum indicator declined from A to B this week, while the relative strength index moved from overbought territory into neutral range. Despite these weakening technical conditions, the stock maintains an undervalued status according to TickrTrends' derived valuation metrics.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AMPH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), AMPH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is AMPH's TickrTrends verdict?
AMPH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does AMPH compare to other Healthcare stocks?
AMPH ranks #27 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is AMPH overbought or oversold?
AMPH's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does AMPH report earnings next?
AMPH's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does AMPH usually beat earnings estimates?
Over its last 8 reported quarters AMPH beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AMPH?
Of 7 analysts covering AMPH, 0 rate it a buy, 6 a hold and 1 a sell - hold-leaning, with a consensus price target of $22.5 (-13.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
AMPH vs ABT · AMPH vs CI · AMPH vs DVA · AMPH vs HSTM · AMPH vs INCY